retatrutide mechanism triple agonist gip glp1 glucagon Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Is retatrutide better than tirzepatide?
Pay in 4 interest-free payments of $6.32 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27









/assets/images/provider/photos/2775923.jpeg)












